An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions
Winnie Chua(University of Birmingham), Larissa Fabritz(University of Birmingham), Paul Brady(University Hospitals Birmingham NHS Foundation Trust), František Neháj(Sandwell & West Birmingham Hospitals NHS Trust), Stefan Kääb(LMU Klinikum), Eduard Guasch(Centro de Investigación en Red en Enfermedades Cardiovasculares), Stef Zeemering(Maastricht University), Moritz F. Sinner(LMU Klinikum), Jasmeet S. Reyat(Cardiovascular Institute Hospital), Ulrich Schotten(Maastricht University), Paulus Kirchhof(University of Birmingham), Laura C. Sommerfeld(Universität Hamburg), Lluı́s Mont, Peter Kastner(Roche Pharma AG (Germany)), Barbara Casadei(John Radcliffe Hospital), Elton Dudink(Maastricht University), Victor Roth Cardoso(University of Birmingham), Georgios V. Gkoutos(University of Cambridge), Harry J.G.M. Crijns, Yanish Purmah(University of Birmingham), Stéphane Hatem, Christoph Al-Taie(Universität Hamburg), André Ziegler(Roche (Switzerland))
Cited by 28
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
|EP Europace|2016|6.5k
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
|European Heart Journal|2016|6.4k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k